Lebsanan (Tacrolimus)

Tacrolimus binds to the intracellular protein FKBP‑12, forming a complex that blocks calcineurin activity. This inhibition prevents activation of T‑cells and the release of inflammatory cytokines, thereby decreasing skin inflammation and pruritus.

The dosage of Lebsanan is individualized by the prescribing clinician based on the severity of the skin condition, the area to be treated, and patient factors. Patients should follow the exact instructions provided by their healthcare professional.

Safety data for topical tacrolimus in pregnancy and lactation are limited. Healthcare providers usually weigh the benefits against potential risks before prescribing. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their physician.

To request Lebsanan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lebsanan (tacrolimus) and other topical calcineurin inhibitors such as pimecrolimus share a similar mechanism of reducing T‑cell activation. Tacrolimus generally offers a broader potency range and is often chosen for moderate to severe atopic dermatitis, while pimecrolimus may be preferred for milder disease or sensitive areas.

Lebsanan should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and efficacy.

Apply a thin layer of Lebsanan to the affected skin area once or twice daily, as directed by the prescriber. Gently rub the medication into the skin until it disappears, and wash hands before and after application to avoid accidental exposure.

Serious risks include secondary skin infections, allergic reactions, and the potential for systemic immunosuppression with extensive use. Long‑term therapy may carry a theoretical risk of skin malignancies, so regular dermatologic monitoring is advised.

Lebsanan is contraindicated in patients with known hypersensitivity to tacrolimus or any formulation components, and it should not be used on infected, ulcerated or compromised skin without medical guidance. Individuals with active systemic infections or those receiving systemic immunosuppressants should consult their physician before use.